A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With Acute Severe Hypertension Recently Discharged From the Hospital

The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently discharged from the hospital, after treatment for acute severe hypertension.

开始日期2026-04-20

申办/合作机构

Kardigan, Inc.

NCT06864104

/ Completed临床2期

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Monthly Subcutaneous Administration of Tonlamarsen in Participants With Uncontrolled Hypertension (KARDINAL)

The purpose of this study is to evaluate the blood pressure (BP)-lowering efficacy of tonlamarsen in adult participants who, despite taking 2 or more antihypertensive medications, have not achieved their target blood pressure (BP).

开始日期2025-04-10

申办/合作机构

Kardigan, Inc.

NCT05314439

/ Completed临床2期

A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Monthly Subcutaneous Administration of ION904 in Patients With Uncontrolled Hypertension

The purpose of this study is to evaluate the effect of ION904 on plasma angiotensinogen (AGT) in participants with uncontrolled hypertension.

开始日期2022-04-29

申办/合作机构

Ionis Pharmaceuticals, Inc.

100 项与 Tonlamarsen 相关的临床结果

登录后查看更多信息

100 项与 Tonlamarsen 相关的转化医学

登录后查看更多信息

100 项与 Tonlamarsen 相关的专利（医药）

登录后查看更多信息

项与 Tonlamarsen 相关的新闻（医药）

2026-04-04

·药明康德

每月一次，治疗高血压的ASO疗法获积极临床试验结果；FDA再批准渤健ASO疗法…… | TIDES周报

近期，全球多肽和寡核苷酸（TIDES）领域迎来系列进展。每月一次皮下注射的反义寡核苷酸（ASO）药物tonlamarsen的2期临床试验结果积极，治疗后第20周，患者的门诊收缩压（oSBP）出现具有临床意义的下降。美国FDA批准ASO疗法Spinraza（nusinersen）高剂量给药方案，用于治疗脊髓性肌萎缩症（SMA）。信达生物公布了玛仕度肽注射液在中国肥胖受试者中开展的2期9 mg剂量的研究结果，在第24周时较安慰剂校正后的减重幅度达15.4%。工程化tRNA疗法AP003在澳大利亚获批启动1期临床试验。本文将节选其中部分重要进展做简单介绍，仅供读者参阅。 Tonlamarsen：公布2期临床试验数据 Kardigan公司公布了其靶向血管紧张素原（AGT）的ASO药物tonlamarsen的2期临床试验KARDINAL结果。Tonlamarsen是一款每月一次皮下注射的在研药物，通过抑制肝脏中AGT的生成，从源头调节肾素-血管紧张素-醛固酮系统（RAAS），旨在为急性重度高血压患者提供一种潜在的血压管理方案。Tonlamarsen由Ionis Pharmaceuticals公司发现和开发，Kardigan从Ionis Pharmaceuticals获得了该药的全球独家开发和商业化授权。此次公布的结果显示，从基线到接受tonlamarsen治疗后第20周，患者的血浆AGT水平显著下降，oSBP也有临床意义上的降低（-6.7 mmHg）。每月给药组患者在第20周时平均AGT水平降低67%，而单次给药组患者的平均AGT水平降低了23%。在血压控制方面，基线血压较高（>150 mmHg）的患者oSBP的降幅最大，为-8.9 mmHg。在安全性上，tonlamarsen总体耐受性良好，未出现有临床意义的治疗相关低血压或高钾血症，其良好的疗效和安全性数据支持了公司在急性重度高血压患者中启动2b期临床试验的计划。 Nusinersen：获美国FDA批准高剂量给药方案渤健（Biogen）宣布，美国FDA已批准其ASO疗法Spinraza（nusinersen）高剂量给药方案，用于治疗脊髓性肌萎缩症。Spinraza是渤健和Ionis Pharmaceuticals联合开发的一款ASO药物。它通过与SMN2基因转录形成的mRNA相结合，改变RNA的剪接过程，从而增加正常SMN蛋白的表达量。因此，这一疗法可以在SMN1基因失活的SMA患者身上增加正常SMN蛋白的水平，从而维持运动神经元的生存。2016年底，Spinraza获得FDA批准上市，成为首款治疗SMA的疗法。该疗法曾获2017年美国盖伦奖（Prix Galien USA Awards）中的最佳生物技术产品奖。此次获批的高剂量方案包括50 mg/5 mL和28 mg/5 mL两种剂量，是在低剂量Spinraza（12 mg）基础上开发而成。通过在起始剂量期和维持期提供更高药物浓度，高剂量方案旨在为SMA患者群体提供新的治疗选择，以更好满足持续存在的治疗需求。该批准主要基于2/3期DEVOTE研究数据，其中关键队列结果显示，在此前未接受治疗且出现症状的婴儿患者中，高剂量Spinraza在运动功能改善方面达到统计学显著差异。以CHOP-INTEND评分评估，与ENDEAR研究中预设的未治疗匹配对照组相比，治疗组平均差异为26.19分（+15.1 vs. -11.1，p<0.0001）。玛仕度肽：公布2期临床试验数据信达生物公布了玛仕度肽注射液在中国肥胖受试者中开展的2期9 mg剂量的临床研究结果。玛仕度肽是信达生物与礼来（Eli Lilly and Company）共同推进的一款胰高血糖素（GCG）/胰高血糖素样肽-1（GLP-1）双受体激动剂。作为一种哺乳动物胃泌酸调节素（OXM）类似物，玛仕度肽除了通过激动GLP-1受体促进胰岛素分泌、降低血糖和减轻体重外，还可通过激动GCG受体增加能量消耗增强减重疗效，同时改善肝脏脂肪代谢。玛仕度肽已在多项临床研究中展现出优秀的减重和降糖疗效，能够降低腰围、血脂、血压、血尿酸、肝酶及肝脏脂肪含量，并改善胰岛素敏感性，带来多重代谢获益。玛仕度肽注射液高剂量9 mg用于成人中重度肥胖患者长期体重控制的上市申请已于2025年11月获中国国家药品监督管理局（NMPA）药品审评中心（CDE）受理。此次公布的2期结果显示，玛仕度肽9 mg治疗组在第24周时较安慰剂校正后的减重幅度达15.4%，心血管代谢指标改善，83.3%的受试者肝脏脂肪含量转至正常（低于5%）。第48周时减重疗效进一步提升，经安慰剂校正后的减重幅度可达18.6%，心血管代谢指标基本维持。安全性方面，玛仕度肽9 mg的耐受性良好，无受试者因不良事件提前终止治疗。 AP003：在澳大利亚获批启动1期临床试验 Alltrna公司宣布，澳大利亚治疗用品管理局（TGA）批准其启动AP003的1期临床试验。AP003是一款经过化学修饰的工程化tRNA疗法，封装在肝脏靶向脂质纳米颗粒中，正在开发用于治疗携带精氨酸转TGA（Arg-TGA）无义突变的肝脏终止密码子疾病患者。该候选疗法旨在通过读取提前终止密码子（PTC），在RNA翻译为蛋白质时重新引入精氨酸到生长中的多肽链中，恢复蛋白质生成。新闻稿指出，AP003是全球首个进入临床试验阶段的tRNA疗法。在临床前模型中，AP003已被证明能够在由共享PTC驱动的疾病环境中恢复全长蛋白表达和下游功能活性。此外，临床前安全性评估显示，AP003的安全性特征与现有的寡核苷酸及脂质纳米颗粒疗法一致，支持其在人体中的进一步临床评估。这些数据支持Alltrna在多种由共享PTC驱动的疾病中评估AP003的广泛临床策略。一体化平台助力寡核苷酸药物开发在寡核苷酸药物快速发展的背景下，其复杂的化学修饰形式、多阶段代谢过程以及体内低暴露水平，使生物分析面临显著高于传统小分子的技术挑战。围绕这一需求，药明康德DMPK团队建立了基于液相色谱-串联质谱（LC-MS/MS）的系统化分析平台，用于寡核苷酸药物及其活性代谢产物的高灵敏检测与高分辨分离，支持从早期研究到临床前阶段的连续研究需求。LC-MS/MS结合液相色谱优异的分离能力与质谱检测的高选择性，可在复杂生物基质中实现对母体寡核苷酸及其代谢片段的精准定量与结构解析，为药代动力学与代谢机制研究提供关键数据基础。针对寡核苷酸分子强亲水性、离子化效率受限以及易形成金属加合物等分析难点，药明康德通过优化样品前处理流程、离子对色谱体系及质谱参数设置，建立了适用于不同修饰类型寡核苷酸的分析策略，包括流动相组成调控与梯度洗脱优化，从而显著提升目标分子与代谢产物之间的分离度与检测灵敏度。同时，通过对多电荷离子信号的系统调控与方法学验证，团队能够在低浓度样品中保持良好的重复性与定量准确性，为PK、PD及安全性研究提供可靠数据支持。依托成熟的寡核苷酸DMPK研究经验与标准化生物分析流程，药明康德可实现母药与活性代谢产物的同步检测与关联分析，帮助研发团队深入理解体内代谢转化路径与暴露特征，为核酸药物的结构优化与开发决策提供坚实的分析基础。参考资料： [1] 全年减重超30斤，玛仕度肽9mg剂量在大体重中国人群中开展的II期临床研究结果在Cell子刊MED发布. Retrieved April 2, 2026, from https://mp.weixin.qq.com/s/cIH-3bJCoJuA_vQH0J_K_A [2] Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Retrieved March 30, 2026, from https://feeds.issuerdirect.com/news-release.html?newsid=8572882090629309&symbol=PTGX [3] 中国国家药监局药品审评中心（CDE）官网. Retrieved April 2, 2026, from https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [4] Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity. Retrieved March 30, 2026 from https://investors.biogen.com/news-releases/news-release-details/biogen-announces-second-positive-phase-2-litifilimab-trial [5] Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate. Retrieved April 2, 2026, from https://avacta.com/avacta-announces-first-patient-treated-in-phase-1-focus-01-trial-of-fap-exd-ava6103-a-sustained-release-precision-exatecan-peptide-drug-conjugate/ [6] 元思生肽（Syneron Bio）完成1.5亿美元B轮融资，引领大环肽药物研发新范式. Retrieved April 2, 2026, from https://www.vbdata.cn/newsDetail/f7fe90c62cd311f1960800163e034e34 [7] Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC. Retrieved April 2, 2026, from https://www.businesswire.com/news/home/20260328084287/en/Kardigan-Announces-Positive-Phase-2-Data-for-Tonlamarsen-in-Patients-with-Uncontrolled-Hypertension-Presented-as-Late-Breaker-at-ACC.26-and-Simultaneously-Published-in-JACC [8] Alltrna Announces Approval to Initiate First-in-Human Clinical Trial of AP003, the First tRNA Therapeutic to Enter Clinical Trials. Retrieved April 2, 2026, from https://www.prnewswire.com/news-releases/alltrna-announces-approval-to-initiate-first-in-human-clinical-trial-of-ap003-the-first-trna-therapeutic-to-enter-clinical-trials-302728901.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

2026-04-02

·国际糖尿病idiabetes

ACC.26 | 面对降压的“天花板效应”，源头截流是否更有效？——KARDINAL Ⅱ期研究结果发布

点击“蓝字”关注我们编者按：在心血管医生的诊室里，最让人头疼的不是不吃药的患者，而是那些遵医嘱服药但血压依然岿然不动的患者。这种现象，我们称之为“难治性高血压”。难道人类的降压治疗真的存在一层无法逾越的“天花板”吗？近日，在2026年美国心脏病学会年会（ACC.26）上，Luke Laffin教授带来了关于新型降压药物Tonlamarsen的KARDINAL Ⅱ期研究最新结果，试图为我们揭开谜底。该研究成果同步发表在Journal of the American College of Cardiology。什么是降压“天花板效应”？——当人体启动了代偿机制所谓降压的“天花板效应”，是指在高血压治疗中，随着药物种类和剂量的不断增加，血压下降幅度却逐渐趋于平缓甚至停滞，同时副作用开始反扑。这背后的原因是人体的代偿机制：当用ACEI堵住了A通道，机体会选择绕过该通道，通过B途径（例如，非ACE途径产生的血管紧张素Ⅱ）或者通过反射性提高心率、增加钠水重吸收来维持血压。这种“你追我赶”的博弈，使得传统药物在进入多药联用阶段后，往往陷入了“加药不降压”的泥潭。治疗困境：难治性高血压引发的恶性循环目前难治性高血压的治疗面临巨大挑战，患者在长期降压治疗中，最隐性的代价是药物不断叠加所引发的副作用，以及由此导致的依从性下降所形成的恶性循环。多种药物叠加给患者带来的负担相当沉重，例如，利尿剂可能引发电解质紊乱，钙通道阻滞剂常导致下肢水肿，而多药联用还可能造成肾功能波动。这种治疗模式不仅增加了生理风险，也显著降低了患者的生活质量。更重要的是，这种复杂的用药方案对依从性提出了极高要求。每天需要精确服用四到五种药物的患者经常会有持续的紧张与不确定性，这也往往成为压垮依从性的最后一根稻草。从机制上看，肾素-血管紧张素-醛固酮（RAS）系统是人体血压调控的“中枢指挥系统”。目前主流的降压药物，如ACEI和ARB，主要作用于RAS系统的中下游环节。这类似于在河流中游筑坝：如果上游水源持续不断，下游的阻断终究存在被“溢流”的风险。因此，研究者逐渐将目光转向更上游的调控环节——由肝脏合成的血管紧张素原（AGT）。通过在源头减少底物供给，或许可以从根本上阻断RAS系统的过度激活，从而为难治性高血压提供一种全新的治疗路径。什么是AGT？揭秘血压调节的“源头活水” 如果把人体调节血压的RAS系统比作一条精密运行的“升压物质生产线”，那么AGT就是这条生产线上最源头、最基础的“原材料”。AGT主要由肝脏合成并释放到血液中，其本身并无升压作用，但通过以下两步“变形”后，演变成了血压的幕后推手：第一步（裁剪）：当血压下降时，肾脏会分泌一种叫“肾素”的酶。它像一把精准的剪刀，将血液中的AGT剪开，转化为血管紧张素Ⅰ。第二步（激活）：血管紧张素Ⅰ在转换酶的作用下，进一步蜕变为强大的血管紧张素Ⅱ。这才是导致血管剧烈收缩、血压飙升的“罪魁祸首”。 “源头截流”即可大力出奇迹？未必！ KARDINAL 研究提出了一种具有颠覆性的治疗假设：与其在RAS系统的下游反复“筑坝控流”，不如在源头直接“釜底抽薪”，从根本上减少升压信号的产生。基于这一思路，研究引入了一种创新性的反义寡核苷酸药物——Tonlamarsen。该药物能够选择性进入肝细胞，通过干扰AGT的基因表达，从源头抑制其合成过程，实现对RAS系统的上游调控。为了验证该假设，研究共纳入198例难治性高血压患者。所有入组患者在联合使用2～5种降压药物（其中超过80%已包含ACEI或ARB）的情况下，诊室收缩压仍高于135mmHg，提示常规治疗控制不佳。研究采用随机、双盲、安慰剂对照设计。所有患者在导入期均接受一次Tonlamarsen注射，随后按随机分配进入Tonlamarsen治疗组或安慰剂组，干预持续20周（见图1）。主要终点为评估干预前后血浆AGT水平及收缩压（SBP）的变化，以反映药物对 RAS 系统源头调控及降压效果的影响。次要终点包括安全性评估、动态血压监测结果，以及单次给药与多次给药方案之间疗效差异的比较。图1. KARDINAL 研究设计研究结果发现：与安慰剂组相比，Tonlamarsen治疗组的血浆AGT水平显著降低了67.2%（图2）。图2. Tonlamarsen治疗组与安慰剂组的血浆AGT水平变化两组的诊室收缩压（SBP）降幅无统计学上差异（图3）。图3. Tonlamarsen 治疗组与安慰剂组的诊室收缩压（SBP）变化安慰剂组的患者中（在导入期接受过一次Tonlamarsen单剂量给药），其AGT水平在20周后依然保持了约23%的残余抑制。在为期5个月的治疗过程中，Tonlamarsen表现出良好的安全性，未观察到严重的电解质紊乱或与药物相关的显著不良事件（表1）。表1. Tonlamarsen 治疗组与安慰剂组的不良事件发生率简而言之，KARDINAL试验证实：在已经联用多种药物的顽固性高血压患者中，Tonlamarsen可以有效地降低血浆AGT水平，但未显著降低患者的SBP。为何“源头截流”未能实现显著降压？尽管KARDINAL研究表明，Tonlamarsen在机制上实现了对AGT的显著抑制，但其降压效果并未呈现出预期效果。作者认为原因可能有以下几方面： 1.入组患者均为接受2~5种降压药的难治性高血压人群，ACEi/ARB等药物已阻断RAAS下游通路，大幅削弱了抑制上游AGT的潜在降压作用； 2：Tonlamarsen产生了意料之外的AGT持久抑制作用，导致安慰剂组在单次给药后20周仍存在残留降压效应，掩盖了治疗组多次给药的降压作用。 3：Tonlamarsen单次AGT抑制作用触发了机体的长期生理代偿，无需持续抑制即可维持降压效果，导致持续每月给药无法产生额外作用。 “意外收获”：从疗效强度到疗效持续性的转变尽管Tonlamarsen的降压效果并未突破难治性高血压的“天花板效应”，但研究也揭示了一个具有潜在变革意义的发现，即Tonlamarsen通过抑制AGT合成可能带来显著而持久的降压作用。研究显示，即便在停止给药后，Tonlamarsen对AGT的抑制作用仍可持续数月。这种“长效源头控制”的特性，为高血压治疗提供了新的可能路径——对于部分患者，未来或可通过“季度一次”甚至“半年一次”的给药方式，实现对血压的长期稳定控制，从而减少对每日口服多种药物的依赖。这一模式的转变，不仅有望改善治疗依从性，也可能在一定程度上重塑高血压的长期管理策略。小结： KARDINAL Ⅱ 期临床试验探索了从RAS系统上游抑制AGT合成对难治性高血压的治疗作用。尽管Tonlamarse实现了血浆AGT水平的显著降低且药物安全性良好，但未展现出显著的降压效果。然而，研究却发现该药物对AGT的抑制具有长效性，为高血压长效治疗、提升患者治疗依从性提供了新的探索方向。参考文献：1.Laffin LJ, et al. Efficacy of tonlamarsen in patients with uncontrolled hypertension: the KARDINAL phase 2 randomized clinical trial. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.03.0342.Efficacy and Safety of Tonlamarsen in Patients with Uncontrolled Hypertension.American College of Cardiology 2026, Scientific Sessions, Late-Breaking Clinical Trial. March 28, 2026 点击左下角“阅读原文”可查看文章原文声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《心肾代谢时讯》编辑部）

临床2期临床结果

2026-03-30

·EndPoints

'A bit of a surprise': Kardigan's repeat dosing of blood pressure drug has no benefit over single shot

Repeat dosing of an antisense hypertension drug that Kardigan licensed from Ionis Pharmaceuticals did not lower patients’ blood pressure better than a single dose, according to Phase 2 data reported on Saturday. The KARDINAL trial, presented at the American College of Cardiology meeting in New Orleans, had an unusual design. All the patients received a single 90 mg injection of the antisense oligonucleotide, called tonlamarsen, and were then randomized into two groups. One had four more monthly doses of the drug, and the others four placebo shots. There was no significant difference between the groups in systolic blood pressure, as measured in a doctor’s office. This was due to “an unexpected, prolonged reduction in blood pressure in the single-dose arm,” Kardigan said . An additional analysis of that co-primary endpoint found that both treatment groups had a blood pressure drop of about 6.7 mmHg at the five-month point, which the company called clinically meaningful. The patients in the study had treatment-resistant hypertension, and were already on between two and five blood pressure medications. Kardigan’s CEO Tassos Gianakakos told Endpoints News that the results indicate that the single dose worked better than expected on the blood pressure measure, rather than the multi-dose cohort doing worse. “What was honestly a bit of a surprise for us is the fact that a single dose had a prolonged effect on systolic blood pressure,” Gianakakos said. In the single-dose arm, the company had “very much expected the systolic blood pressure to return pretty darn near close to baseline.” The finding is somewhat confusing, since on a mechanistic level, the drug does seem to work as intended. In another co-primary endpoint, the repeat-dose regimen cut levels of the protein tonlamarsen targets, which is called angiotensinogen or AGT, to a significantly greater degree than the single dose. Those in the five-shot group saw their AGT levels fall 67%, whereas the single-dose cohort had a 23% reduction. Tonlamarsen has a similar mechanism to Alnylam’s zilebesiran, an siRNA therapeutic that silences hepatic AGT expression. Zilebesiran misfired in a mid-stage trial last year. Alnylam is conducting a whopping 11,000-patient Phase 3 cardiovascular outcomes trial with the drug. Gianakakos said these two products act slightly differently. As an antisense oligonucleotide, tonlamarsen can modulate the levels of AGT more precisely than zilebesiran, he said. In the write-up of the trial published in JACC , the investigators wrote that “subsequent trials will need to compare tonlamarsen strictly with placebo and forego an active run-in period to definitively demonstrate the magnitude of [blood pressure] reduction.” And that is what Kardigan intends to do, albeit in a slightly different population. The company is planning to kick off a Phase 2b trial named KARDINAL-ASH in patients who have been hospitalized for acute severe hypertension (ASH) later this year. “These are folks who die from aortic rupture and aneurysm, from heart failure and renal disease. And they are in and out of the hospital,” Gianakakos said, adding that this will be the first drug trial specifically in this population. The trial will enroll patients upon discharge and aim at “keeping them out of trouble” for the subsequent 90 days, Gianakakos said. Although what “out of trouble” means is yet to be defined, it could be getting their systolic blood pressure under 180 mmHg or 160 mmHg — “something like that.” This is higher than blood pressure guidelines suggest, but he pointed out that in these very sick patients, it is still a meaningful goal. The trial will also aim to provide evidence that tonlamarsen can reduce surges in blood pressure, and patients will be constantly tracked with wearable monitors. This is prompted by a post-hoc analysis of the Phase 2 trial presented at ACC, which found that patients in the five-dose group had a 28% decrease in surges in systolic blood pressure above 150 mmHg relative to the one-dose cohort. “If we keep people in the safe zone, we expect to see things like reductions in hospitalizations and improvements in mortality related to this end organ failure,” Gianakakos said. He could not specify when the trial will report, though he said the company feels “a sense of urgency,” and wants to get it done as quickly as possible. If tonlamarsen makes it all the way to market, it will likely enter a very different environment to the one that exists now. An approval decision for AstraZeneca’s resistant hypertension pill baxdrostat is imminent, and its pivotal data were very strong . A similarly acting pill from Mineralys Therapeutics — both are aldosterone synthase inhibitors — could also gain approval towards the end of this year. Gianakakos said this should not limit tonlamarsen’s market potential, since these drugs act on a separate biological pathway. “They’re related, and I think they could be synergistic,” he said. But the aldosterone synthase inhibitors might not be able to prevent the surges seen in ASH patients. Kardigan emerged in January 2025 with $300 million in funding. Two months later, Endpoints reported that it had licensed tonlamarsen from Ionis.

临床2期临床结果临床3期寡核苷酸

100 项与 Tonlamarsen 相关的药物交易

登录后查看更多信息